Ella Sorani

867 total citations
21 papers, 100 citations indexed

About

Ella Sorani is a scholar working on Oncology, Hematology and Immunology. According to data from OpenAlex, Ella Sorani has authored 21 papers receiving a total of 100 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 9 papers in Hematology and 8 papers in Immunology. Recurrent topics in Ella Sorani's work include Acute Myeloid Leukemia Research (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Ella Sorani is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Ella Sorani collaborates with scholars based in United States, Israel and Germany. Ella Sorani's co-authors include Amnon Peled, John F. DiPersio, Osnat Bohana‐Kashtan, Geoffrey L. Uy, Liat Hayardeny, Daniel C. Link, Jonathan E. Brammer, Zachary Crees, Fred Lühder and Friedemann Paul and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Ella Sorani

20 papers receiving 100 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ella Sorani United States	6	45	44	16	16	13	21	100
Carlo Tur Germany	3	42 0.9×	39 0.9×	11 0.7×	8 0.5×	8 0.6×	10	87
Laetitia Claër France	5	168 3.7×	39 0.9×	33 2.1×	9 0.6×	8 0.6×	7	206
Ekaterina Postovalova United States	6	27 0.6×	33 0.8×	27 1.7×	9 0.6×	6 0.5×	25	98
Kaitlyn A. Lagattuta United States	4	96 2.1×	39 0.9×	40 2.5×	7 0.4×	5 0.4×	7	143
Artur Wilhelm Germany	4	57 1.3×	46 1.0×	13 0.8×	8 0.5×	9 0.7×	4	104
Dominik Trzupek United Kingdom	4	94 2.1×	43 1.0×	35 2.2×	5 0.3×	7 0.5×	6	156
Anika Janssen Germany	7	107 2.4×	45 1.0×	31 1.9×	6 0.4×	3 0.2×	15	154
Adam J. Widman United States	7	36 0.8×	43 1.0×	21 1.3×	8 0.5×	9 0.7×	12	116
Rosalie de Beaumont United States	3	43 1.0×	51 1.2×	31 1.9×	10 0.6×	34 2.6×	3	104
Siok Ping Yeo Singapore	4	28 0.6×	42 1.0×	48 3.0×	13 0.8×	3 0.2×	4	98

Countries citing papers authored by Ella Sorani

Since Specialization

Citations

This map shows the geographic impact of Ella Sorani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ella Sorani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ella Sorani more than expected).

Fields of papers citing papers by Ella Sorani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ella Sorani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ella Sorani. The network helps show where Ella Sorani may publish in the future.

Co-authorship network of co-authors of Ella Sorani

This figure shows the co-authorship network connecting the top 25 collaborators of Ella Sorani. A scholar is included among the top collaborators of Ella Sorani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ella Sorani. Ella Sorani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leonard, Alexis, Akshay Sharma, Yogindra Persaud, et al.. (2024). Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease. Blood. 144(Supplement 1). 2100.1–2100.1. 2 indexed citations

Crees, Zachary, Michael P. Rettig, Reyka G. Jayasinghe, et al.. (2024). Motixafortide (CXCR4 Inhibition) Alone and in Combination with Natalizumab (VLA-4 Inhibition) As a Novel Regimen to Mobilize Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease: A First-in-Human, Proof-of-Principle Safety and Feasibility Study. Blood. 144(Supplement 1). 145–145. 2 indexed citations

Crees, Zachary, et al.. (2024). Prolonged CXCR4 Receptor Occupancy By Motixafortide Following a Single Subcutaneous Injection Is Associated with Extended Mobilization of CD34+ Cells in Peripheral Blood for > 24 Hours. Transplantation and Cellular Therapy. 30(2). S390–S390. 1 indexed citations

Crees, Zachary, Keith Stockerl‐Goldstein, Mark A. Schroeder, et al.. (2023). Use of Combination Premedication Prior to Motixafortide Administration Reduced Severity and Frequency of AEs in the Phase 3 Genesis Trial - a Single Center Analysis. Blood. 142(Supplement 1). 3522–3522.

Crees, Zachary, Michael P. Rettig, Reyka G. Jayasinghe, et al.. (2022). A Phase I Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) As a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapy in Sickle Cell Disease. Blood. 140(Supplement 1). 10432–10433. 2 indexed citations

Crees, Zachary, Reyka G. Jayasinghe, Keith Stockerl‐Goldstein, et al.. (2021). Immunophenotypic and Single-Cell Transcriptional Profiling of CD34+ Hematopoietic Stem and Progenitor Cells Mobilized with Motixafortide (BL-8040) and G-CSF Versus Plerixafor and G-CSF Versus Placebo and G-CSF: A Correlative Study of the Genesis Trial. Blood. 138(Supplement 1). 3816–3816. 1 indexed citations

Abraham, Michal, et al.. (2021). The High Affinity CXCR4 Inhibitor, BL-8040, Impairs the Infiltration, Migration, Viability, and Differentiation of Regulatory T Cells. Blood. 138(Supplement 1). 2804–2804. 2 indexed citations

Xia, Jun, Stephanie Sun, Geoffrey L. Uy, et al.. (2020). Combined Inhibition of CXCR4 Signaling and System xc- Transporter Activity Induces Synthetic Lethality in T-ALL Cells By Suppressing Gsh and Inducing Ferroptosis. Blood. 136(Supplement 1). 37–37. 3 indexed citations

Shaw, Stephen M., Kim Wigglesworth, Oliver Schulz, et al.. (2019). AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models. Cancer Cell International. 19(1). 346–346. 12 indexed citations

10.

Xia, Jun, Stephanie Sun, Geoffrey L. Uy, et al.. (2019). CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death. Blood. 134(Supplement_1). 2745–2745. 3 indexed citations

11.

Uy, Geoffrey L., Tapan M. Kadia, Wendy Stock, et al.. (2019). CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma. Blood. 134(Supplement_1). 2630–2630. 8 indexed citations

12.

Hidalgo, Manuel, Valerya Semenisty, Bruno Bockorny, et al.. (2019). A Multi-Center Phase IIA Trial to Assess the Safety and Efficacy of BL-8040 (a CXCR4 Inhibitor) in Combination with Pembrolizumab and Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC). Annals of Oncology. 30. xi33–xi33. 12 indexed citations

13.

Rettig, Michael P., Geoffrey L. Uy, Asad Bashey, et al.. (2018). Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product. Blood. 132(Supplement 1). 118–118. 1 indexed citations

14.

Hidalgo, Manuel, Ron Epelbaum, Ravit Geva, et al.. (2018). Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.. Journal of Clinical Oncology. 36(5_suppl). 88–88. 4 indexed citations

15.

Hidalgo, Manuel, Ron Epelbaum, Brian M. Wolpin, et al.. (2018). A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC). Annals of Oncology. 29. viii402–viii402. 4 indexed citations

16.

Xia, Jun, Stephanie Sun, Geoffrey L. Uy, et al.. (2018). The CXCR4 Antagonist, BL8040, Is Highly Active Against Human T-ALL in Preclinical Models. Blood. 132(Supplement 1). 2700–2700. 2 indexed citations

17.

Fogelman, David R., Steven M. Townson, Gauri R. Varadhachary, et al.. (2018). A pilot study to assess the efficacy, safety, and pharmacodynamic effects of pembrolizumab and BL-8040 in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology. 36(4_suppl). TPS533–TPS533. 2 indexed citations

18.

Gaur, Pankaj, Vivek Verma, Seema Gupta, et al.. (2018). CXCR4 antagonist (BL-8040) to enhance antitumor effects by increasing tumor infiltration of antigen-specific effector T-cells.. Journal of Clinical Oncology. 36(5_suppl). 73–73. 7 indexed citations

19.

Lühder, Fred, Hania Kébir, Francesca Odoardi, et al.. (2017). Laquinimod enhances central nervous system barrier functions. Neurobiology of Disease. 102. 60–69. 15 indexed citations

20.

Ziemssen, Tjalf, Hayrettin Tumani, Katja Thomas, et al.. (2017). Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. Journal of Neuroinflammation. 14(1). 172–172. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact